Pages that link to "Q40290699"

The following pages link to Brigitte Pegourie (Q40290699):

Displaying 29 items.

• Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial (Q28252396) (← links)
• Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R (Q33401216) (← links)
• Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du (Q33416427) (← links)
• VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial (Q33430928) (← links)
• Complications and treatment of patients with β-thalassemia in France: results of the National Registry (Q33829058) (← links)
• Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. (Q34574044) (← links)
• Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience (Q37033951) (← links)
• Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma (Q37528072) (← links)
• Heavy   light chain analysis to assign myeloma response is analogous to the IMWG response criteria (Q38373226) (← links)
• Partial Response at Completion of Bortezomib-Thalidomide-Dexamethasone (VTd) Induction Regimen Upfront in Multiple Myeloma Does Not Preclude Response to VTd in Consolidation (Q38418528) (← links)
• Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results (Q39062058) (← links)
• Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients (Q39210735) (← links)
• Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02. (Q39485433) (← links)
• Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial (Q42940540) (← links)
• Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). (Q43250016) (← links)
• Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. (Q46006794) (← links)
• Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. (Q47826998) (← links)
• Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma (Q48214002) (← links)
• Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. (Q48250873) (← links)
• Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial (Q49041464) (← links)
• Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma (Q57034183) (← links)
• Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma (Q57151125) (← links)
• Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma (Q58415969) (← links)
• Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome (Q58415971) (← links)
• Maintenance therapy with thalidomide improves survival in patients with multiple myeloma (Q80011690) (← links)
• Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial (Q82564216) (← links)
• Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma (Q84783323) (← links)
• Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 (Q88470620) (← links)
• Predictive factors of survival after thalidomide therapy in advanced multiple myeloma: long-term follow-up of a prospective multicenter nonrandomized phase II study in 120 patients (Q95423337) (← links)